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I nt h i sw o r k ,w ee v a l u a t e dt h ee ﬀects of administration of OVA on phenotype and function of intraepithelial lymphocytes (IELs)
from small intestine of transgenic (TGN) DO11.10 and wild-type BALB/c mice. While the small intestines from BALB/c presented
a well preserved structure, those from TGN showed an inﬂamed aspect. The ingestion of OVA induced a reduction in the number
of IELs in small intestines of TGN, but it did not change the frequencies of CD8+ and CD4+ T-cell subsets. Administration of OVA
via oral + ip increased the frequency of CD103+ cells in CD4+ T-cell subset in IELs of both BALB/c and TGN mice and elevated
its expression in CD8β+ T-cell subset in IELs of TGN. The frequency of Foxp3+ cells increased in all subsets in IELs of BALB/c
treated with OVA; in IELs of TGN, it increased only in CD25+ subset. IELs from BALB/c tolerant mice had lower expression of
all cytokines studied, whereas those from TGN showed high expression of inﬂammatory cytokines, especially of IFN-γ,T G F - β,
and TNF-α. Overall, our results suggest that the inability of TGN to become tolerant may be related to disorganization and altered
proportions of inﬂammatory/regulatory T cells in its intestinal mucosa.
1.Introduction
Oral tolerance has long been recognized as a physiological
mechanism of immune unresponsiveness to dietary antigens
(Ags) and indigenous bacterial Ags that maintains tissue
integritybypreventingharmfuldelayedtypehypersensitivity
responses in the intestine [1]. Three mechanisms were
postulated to mediate oral tolerance: clonal deletion, anergy,
a n da c t i v ei m m u n es u p p r e s s i o n .L o w e rd o s e so fA gh a v e
favored active suppression, and this mechanism is mediated
through regulatory cytokines such as TGF-β, IL-10, and
IL-4 [2]. T cells producing these regulatory cytokines may
downregulate autoreactive T cells in an antigen nonspeciﬁc
way [2, 3], whereas higher doses favor anergy and T-cell
depletion [3]. More recent results show that an activation
of T cells is necessary before establishing oral tolerance [4],
while enhanced antibacterial immunity can be achieved with
concomitant generation of oral tolerance followed by oral
administration of soluble antigen such as ovalbumin (OVA)
[5].
The immunological consequences of oral administration
of antigen ultimately depend on how antigen is taken up
and presented to T cells by dendritic cells [6]. Despite of the
initiation of oral tolerance remains to be cleared, it seems
to involve the active participation of the all gut-associated
lymphoid tissue (GALT) [7]. Intraepithelial lymphocytes
(IELs) play an important role in the maintenance of mucosal
homeostasis by regulating mucosal innate and acquired
immunity [8]. The populations of IELs exhibit unique
characteristics, perform functions not fully elucidated, and
diﬀer widely from their systemic counterparts [9]. IELs in
mice and humans include large numbers of cells expressing
T-cells receptor (TCRs) αβ and γδ [9]. The majority of IELs
are CD8+ cells that express a CD8αα homodimer. Among2 Clinical and Developmental Immunology
IELs subsets, it can still be found some CD4−CD8−double
negative cells, CD4+CD8+ double positive cells and a few
CD4+CD8αα+ cells [8, 10]. Nearly all CD8+ IELs expressed
CD69 and had lytic activity [11].
Preliminary results of our group have shown that
DO11.10 mice, that bear transgenic anti-OVA TCR, are not
s u s c e p t i b l et oo r a lt o l e r a n c ew i t hO V A[ 12]. In the present
work, we investigated the immune response that takes place
in intestinal mucosa during theconsumption of OVAin both
BALB/c and DO11.10 mice. Since the majority of studies
withoraltoleranceinductionandmucosalimmune response
have only evaluated the role of CD4+αβ T cells [13–15], we
analyzed all subsets of IELs of these mice in the context of
oral tolerance and immune response to OVA.
2.MaterialandMethods
2.1. Animals. Breeder pairs of TCR OVA-speciﬁc trans-
genic mice (clone DO11.10) [16]a n dB A L B / cm i c ew e r e
supplied by CEMIB (Centro Multinstitucional de Investi-
gac˜ oes Biol´ ogicas), UNICAMP. Mice were maintained under
speciﬁc pathogen-free condition and were provided with
autoclaved food and water. The study was approved by the
Ethics Commitee for Animal Experimentation of University
of Campinas (Protocol no. 736-2).
2.2. Tolerance Induction and Immunizations. Oral tolerance
to OVA was induced in 8 weeks old mice as described
elsewhere [12]. Brieﬂy, Mice were fed with 4mg/mL OVA
solution (Rhoster Ind´ ustria e Com´ ercio, Ltda., Vargem
Grande Paulista, SP, Brazil) for seven consecutive days. The
mice in the control group received protein-free water. Seven
days after the interruption of oral treatment, half of this
group of mice was challenged with of 10μgO V A( S i g m a
Chemical Co., St. Louis,MO, USA) plus 1mg Al(OH)3 by
intraperitoneal (ip) route. After 14 days, mice were boosted
with 10μg OVA in saline solution via ip. In control group,
half of the animals were also challenged with the ip doses of
OVA. Seven days after the last ip dose, all mice were bled for
serum separation, and then euthanized in a CO2 chamber.
2.3. Cell Isolation and Puriﬁcation. Intraepithelial lympho-
cytes were isolated from the small intestine of BALB/c
and DO11.10 mice, according to Montufar-Solis and Klein
[17]. Brieﬂy, small intestine tissues were removed, and
Peyer’s patches were dissected out. Tissues were ﬂushed
of fecal material, opened longitudinally, and cut into 3 to
4mm pieces in RPMI 1640 (Sigma-Aldrich) supplemented
with FCS (10% v/v) (Nutricell, Campinas, SP, Brazil), gen-
tamicin 20μg/mL (GE Healthcare Biosciences, Pittsburgh,
PA, USA). Tissue fragments were rinsed several times in
Ca2−/Mg2− free PBS, transferred to Ca2−/Mg2− free PBS
containing 5mM EDTA (Sigma-Aldrich) and 2mM DTT
(Calbiochem; Cleveland’s reagent; Merck KGaA, Darmstadt,
Germany) and shaken (bath Dubnoﬀ-Marconi, Piracicaba,
SP, Brazil) at 37◦C for 30min. Cell suspensions were ﬁltered
through 20-mL syringe barrels containing wetted nylon
wool,centrifuged,suspendedin3mLof40%isotonicPercoll
(Amersham and Sigma-Aldrich), layered on top of 70%
isotonic Percoll (4mL), and centrifuged for 30min at 400xg.
IELs were recovered from the Percoll interface and washed
by centrifugation in supplemented RPMI-1640, viability and
cell numbers were measured by exclusion of Trypan blue
dye and counting in a hemocytometer. IELs from BALB/c
mice were further puriﬁed by immunomagnetic separation,
using beads conjugated with mAb anti-CD90 (Thy-1.2) on
MS columns, as recommended by the manufacturer (Midi
Macs, Miltenyi Biotec, Bergisch-GladBach, Germany).
2.4. Phenotypic Analysis by Flow Cytometry. Single-cell sus-
pensionsfromsmallintestineweresuspendinginPBS/0,01%
BSA (Sigma) w/v supplemented with 0,1% sodium azide.
Cells were ﬁrst incubated with anti-CD16/32 (culture super-
natants of clone 2.4G2) for 45min to block Fc-mediated
antibody binding. Then, cells were incubated with relevant
mAb for 30min at 4◦C, washed with PBS/2% FCS, and
ﬁxed 9 with PBS/1% formaldehyde (Merck Darmstadt,
Germany). Three- or four-color ﬂow cytometry acquisition
was performed on FACSAria (BD Bioscience, San Jose, CA,
USA).Atotalof30.000eventswereacquiredineachanalysis.
The following antibodies purchased from BDPharMingen
were used for ﬂow cytometry: anti-CD3 (clone 145-2C11)-
PerCP Cy5.5 or FITC; anti-CD4 (clone GK1.5)-FITC, PE
or PE-Cy7; anti-CD4 (clone RM4-5)-PE-Cy7; anti-CD8α
(clone 53-6.7)-FITC or PE; anti-CD8β (clone 53-5.8)-FITC;
anti-TCRβ (clone H57-597)-PE; anti-TCRγδ (clone GL3)-
FITC or PE; anti-CD152 (CTLA-4) (clone UC10-4F10-11)-
PE; anti-CD25 (clone 7D4)-FITC or PE; anti-CD103 (α IEL)
(clone M290)-PE; anti-OVA TCR (clone KJ1-26)-PE. Anti-
Foxp 3 (clone FJK-16s)-PE or FITC were purchased from
eBioscience(SanDiego,CA,USA).Datawereanalyzedbythe
software FCS express V3. Respective isotype controls were
included for each cell surface stain to exclude nonspeciﬁc
binding and to determine the optimal setting ﬂuorescence
quadrants (BD Bioscience, San Jose, CA, USA). Data were
analyzed by the software FCS express V3 (De Novo Software,
Los Angeles, CA, USA).
2.5. Histological and Immunohistochemical Staining. For his-
tological analysis, pieces from small intestine were ﬁxed
in 4% paraformaldehyde buﬀered solution (Sigma) and
washed with PBS/1% Glycine (J.T. Baker, Mallinckrodt
Baker, Phillipsburg, NJ, USA), and 5μmp a r a ﬃn-embedded
sections were stained with hematoxylin and eosin (Sigma).
Slides were observed in an optical microscope (Eclipse
E-800 Microscope, NIKON; Tokyo, Japan) and analyzed
using the software Proplus image. For immunoﬂuorescence
analysis, sections of small intestine were dehydrated, frozen
in OCT-embedding compound (Leica) on dry ice, and
stored at −70◦C. Tissue sections (5μm )w e r ec u tw i t ha
cryostat (Microm HM 505 E) and transferred to silane-
coated microscope slides. Cryosections were brought to
room temperature, ﬁxed with acetone (Merck) for 10min
at 4◦C, and blocked with PBS containing 1% of BSA (type
V, INLAB, SP, Brazil) for 30min. After washing with PBS,
they were incubated with anti-CD3 FITC-labelled (cloneClinical and Developmental Immunology 3
Table 1: Number of cells recovered from 40/70%-Percoll interface
Cells from(a,b)
BALB/C DO11.10
Treatments
Control 7.07 ±2.05 4.27 ±1.51
Oral ova 6.50 ±1.91 1.57∗ ±0.72
Oral + IP ova 11.62 ±4.97 1.00∗ ±0.29
IP ova 12.75 ±3.41 0.55∗∗ ±0.08
(a)Number of cells represents the mean ± SEM × 107 cells; (b)Data were obtained from 3-4 independent experiments; ∗P<0.05; ∗∗P<0.01.
145-2C11 homemade) for 3h, washed, and incubated with
TRITC-phalloidin (Sigma) for 30min. All incubations were
made at room temperature. Vectashield-mounted slides
(Vector Laboratories) were visualized by optical microscopy.
2.6. Quantitative Real-Time Polymerase Chain Reaction
(PCR). T o t a lR N Aw a se x t r a c t e df r o mm o u s eI E L su s i n g
PureLink Micro-to-Midi Total RNA Puriﬁcation System
(Invitrogen, SP, Brazil,) according to the manufacturer’s
instructions. The cDNA was made using SuperScript III
First-Strand Synthesis Supermix (Invitrogen) with random
primers (Invitrogen) and analyzed for IL-2, IL-4, IL-10, IL-
6, IL-17, IFN-γ,T G F - β,a n dT N F - α gene expression by real-
time PCR assay using an 7500 Fast Real-Time PCR (Applied
Biosystems, Foster City, CA) according to the manufacturer’s
instructions; 18S ribosomal RNA (rRNA) was used as an
i n t e r n a lc o n t r o l .A l lm o u s ep r i m e ra n dp r o b es e t su s e d
were predesigned TaqMan Gene Expression Assays (Applied
Biosystems). PCRs were performed in four replicates with
a 2x TaqMan Mastermix (Applied Biosystems). Relative
expression of mRNA species was calculated using the com-
parative 2 threshold cycle (ΔCT) method [18].
2.7. Statical Analysis. The statistical analysis was performed
using GraphPad Prism 4 (GraphPad Software, CA, USA).
Thestatisticalsigniﬁcanceofdiﬀerencesbetweencontroland
experimental groups were determined by one-way and two-
way ANOVA, followed by multiple comparison Bonferroni’s
test. The results were expressed as mean ± SEM. Values were
consideredsigniﬁcantatP<0.05.Supplementaldatainclude
two ﬁgures (see supplementary material available online at
doi:10.1155/2012/208054).
3. Results
3.1. Histological Analysis and Distribution of IELs in Small
Intestines of Mice DO11.10 and BALB/c. As depicted in
Figure 1(a), the small intestine histoarchitecture of both
na¨ ıve DO11.10 and BALB/c strains were preserved; however,
it was found reduced tunica muscular thickness of DO11.10
whencomparedwithBALB/cmice.Discretebutwell-deﬁned
histological changes were observed in the lamina propria
(LP) of intestinal villi of the transgenic mice after feeding
with OVA, mainly in those challenged with OVA by ip route,
with a loose connective tissue rupture and mild edema
of lamina propria of villous projections in DO11.10 mice.
BALB/c mice treated with OVA did not present any of those
alterations. The total number of IELs isolated from the
small intestine of DO11.10 mice of all experimental groups
was always lower than those from BALB/c and markedly
dropped upon OVA treatments (Table 1). As illustrated in
Figure 1(b), the incidence of CD3 positive cells decreased
substantially in the villi of TGN mice but not in the BALB/c.
Cytometry analyses of IELs isolated from TGN showed that
the clonotype anti-OVA TCR cells (KJ1-26 positive cells)
decreased signiﬁcantly from 65% to less than 20% after oral
and ip administration of OVA (Figures 1(c) and 1(d)).
3.2. Analysis of Subsets of IELs after the Induction of Tolerance
or Immunization. IELs from BALB/c and D011.10 mice
treated with OVA by oral and/or ip route were stained with
anti-CD3, anti-CD8α, anti-CD8β, anti-CD4 and analyzed
by three-color ﬂow cytometry (Figure 2). As shown in
Figure 2(a),thefrequencyofCD3+ cellsinthesmallintestine
of BALB/c and DO11.10 mice was not changed by diﬀerent
treatments with OVA. No signiﬁcant alteration was observed
inthefrequencyofIELsubsets(CD8αα,CD8αβ,CD4/CD8α,
CD4) upon treatments with OVA (Figure 2(c)).
The eﬀects of administration of OVA on the distri-
bution of phenotypic markers CD103 and CD25 were
assessed in subsets CD4, CD8α, and CD8β of IELs iso-
lated from BALB/c(Supplemental Figure 1, Panel A-D) and
DO11.10 mice(Supplemental Figure 1, Panel (E-H)), as well
as the frequencies of αβ+ and γδ+ T cells in these sub-
sets (Supplemental Figure 2). Frequency and expression of
CD103+ cells in subsets of IELs of BALB/c and DO11.10
mice are illustrated in histograms of (Figures 3(a) and 3(b),
resp.). Signiﬁcant increase of CD4+CD103+ subset of IELs
was observed following treatments with OVA by oral + ip
routes, in both BALB/c and DO11.10 mice, whereas no
antigen-dependent alteration was observed in the frequency
of CD8αα and CD8αβ IELs expressing CD103 (Figure 3(c)).
However, the expression of CD103 was signiﬁcantly aug-
mented in subpopulation of CD8αα+ and CD8αβ+ IELs
w h e nB A L B / cm i c ew e r ef e dw i t hO V A ,a sw e l la si nC D 8 αα+
cells in ip immunized mice. Conversely, in DO11.10 mice,
this marker was signiﬁcantly reduced in CD8αα+ cells upon
immunization with OVA by ip route (Figure 3(c)).
Frequency and expression of CD25+ cells in subsets
of IELs of mice BALB/c and DO11.10 are illustrated in
histograms of (Figures 4 (a) and 4(b) resp.). No antigen-
dependent alteration was observed in the frequency of IELs4 Clinical and Developmental Immunology
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Figure 1: Histological analysis and incidence of T cells in small intestines (jejunum) of BALB/c and DO11.10 mice after treatments with
OVA. Mice were fed with OVA solution for 7 days (oral OVA), fed with OVA and challenged by ip route (oral + ip OVA), immunized
with OVA only by ip route (ip OVA), or non-treated (control). (a) Hematoxylin/Eosin-stained sections of small intestines in low and high
magniﬁcation showing details of mucosa villi. Note the reduced thickness of the tunica muscular (arrow heads) in DO11.10 when compared
with BALB/c, and loss of connective tissue and mild edema in the lamina propria (thin arrows) in Oral + ip OVA and ip OVA groups of
DO11.10 mice. Bars = 50μm. (b) Immunoﬂuorescence of frozen sections of jejunum counterstained with TRITC-phalloidin (red epithelial
cells) showing reduced incidence of CD3 positive cells (green) in the mucosa of DO11.10 in comparison to BALB/c mice. Bars = 25μm; (c,
d) Frequency of KJ1-26 positive cells amongst the intraepithelial lymphocytes freshly isolated from DO11.10 mice treated with OVA. The
clonotype anti-OVA TCR cells (KJ1-26+ cells) decreased from 65% to less than 20% after oral and ip administration of OVA. Data represent
mean ± SEM (N = 5) of three independent experiments.Clinical and Developmental Immunology 5
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Figure 2: Eﬀects of the treatments with OVA on CD4 and CD8 subsets of IELs. Freshly isolated IELs from BALB/c (a) and DO11.10 (b) mice
were gated for CD3+ cells and analyzed for expression of CD8α,C D 8 α/CD8β, and CD4/CD8α by ﬂow cytometry. No signiﬁcant diﬀerence
was found in the frequency of IELs of any subset in both strains of mice. In (c), data represent mean ± SEM (N = 5) in each group in three
independent experiments.
expressing this marker in both DO11.10 and BALB/c mice,
except in CD8β+ subset of IELs in which this marker
was upregulated by treatments with OVA by oral route
(Figure 4(c)).
3.3. Evaluation of Foxp3 Expression in IELs after Administra-
tion of OVA. To assess possible changes in the frequency of
regulatory T cells after oral and/or ip administration of OVA,
IELsfromBALB/candDO11.10micewerestainedwithanti-
Foxp3 and analyzed by ﬂow cytometry in CD4+,C D 8 αα+,
CD8αβ+, and CD25+ subsets. As shown in Figures 5(a)
and 5(c), we observed that oral administration of OVA to
BALB/cmiceresultedinelevationofthefrequencyofFoxp3+
cells in CD4+ and CD8αβ+subsets. Following parenteral
administration of OVA, the frequency of cells Foxp3+ in IELs
of BALB/c mice was more elevated in the CD8αα+,C D 8 αβ+,
and CD25+ subsets. On the other hand, only the oral +
ip treatment of DO11.10 mice increased the frequency of
Foxp3+ cells in the CD25+ subset (Figures 5(b) and 5(c)).
3.4. Eﬀect of Treatments with OVA on Cytokine mRNA
Expression in IELs of BALB/c and DO11.10 Mice. In addition
to phenotypic analysis, expression of pro-(IL-2, IFN-γ,I L -
6, IL-17, and TNF-α) and anti-inﬂammatory (IL-10, IL-4,
and TGF-β) cytokines has been assessed by real-time PCR
from extracts of IELs of the small intestine of BALB/c and
DO11.10micetreatedwithOVA.Theresultsaresummarized
in Figure 6. It is possible to notice that IELs from OVA-
treated mice of both strains present opposite proﬁles in
relation to the gene expression of most cytokines examined.
IELs from tolerant BALB/c mice (oral and oral + ip groups)
showed a diminished expression of mRNA for cytokines
IL-10, IL-2, IFN-γ,T G F - β,a n dT N F - α in comparison to
those from mice immunized by ip route. IELs from DO11.10
mice treated with OVA by oral + ip and ip routes showed
an elevated expression of IL-6, IL17, TNF-α,a n dT G F - β,
although diﬀerences were not signiﬁcant in comparison with
the oral group. IELs from DO11.10 mice that received OVA
by oral + ip, however, showed a mRNA expression for TNF-
α,I F N - γ,a n dT G F - β signiﬁcantly more elevated than IELs
from BALB/c mice of the same group.
4. Discussion
Failure in the induction of oral tolerance seems to be
associated with modiﬁcations in the gastrointestinal mucosa
permeabilityand,especially,withtheimmunoregulationthat
occurs in this environment [19, 20]. Results obtained previ-
ously in our laboratory showed that transgenic DO11.10 and
BALB/c mice diﬀer in their immune response to oral OVA.
While DO11.10 mice develop a speciﬁc humoral immune
response after the ingestion of native ovalbumin, the BALB/c
mice become tolerant to OVA. The transgenic mice fed with
ovalbumin produced an immune response that is a mixedClinical and Developmental Immunology 7
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Figure 3: Eﬀects of the treatments with OVA on the frequency of CD103+ cells in the small intestine. Freshly isolated IELs from BALB/c
(a) and DO11.10 (b) mice were gated for CD3+/CD4+,C D 3 +/CD8α+, and CD3+/CD8β+ cells and analyzed for expression of CD103 by ﬂow
cytometry.Blankhistogramsindicateisotypecontrolstaining.CD3+/CD8β+ subsetillustratedattherightcolumnispartoftheCD3+/CD8α+
population. (c) Data represent mean ± SEM (N = 5) in three independent experiments. Frequency of CD4+ cells were signiﬁcantly more
elevated in IELs isolated from mice BALB/c and DO11.10 treated with OVA by oral + ip routes. The expression of CD103 was markedly
augmented in all subpopulations of IELs of OVA-treated BALB/c mice and was reduced in DO11.10 immunized by ip route.
of TH1/TH2, with prevalence of a TH1 pattern [12]. In this
work, we observed that even before the oral treatment with
OVA, the DO11.10 mice have showed morphological modi-
ﬁcationsintheintestinalepitheliumvilliandofthemuscular
layer in the intestinal tissue. Our results showed a deepening
of changes in the epithelium of small intestine in DO11.10
mice treated with OVA, which are consistent to an inﬂam-
atory process. These changes have not been observed in
the intestinal epithelium of BALB/c mice, which have
been presented a good preservation of the villi. A chronic
inﬂammatory process, with lymphocytic inﬁltration in the
lamina propria and increased number of IELs in the epithe-
lium has been shown in double-transgenic mice that express
the haemagglutinin from inﬂuenza virus A (HA) and TCR
HA-speciﬁc. The inﬂammatory reaction, however, is kept
under control by the generation of regulatory T cells [14].
Deletion of self-reactive lymphocytes constitutes one of
main mechanisms of peripheral tolerance induction and
probably of oral tolerance induction [21, 22]. Conversely,
intestinal inﬂammation has been correlated with failure inClinical and Developmental Immunology 9
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Figure 4: Eﬀects of the treatments with OVA on the frequency of CD25+ cells in the small intestine. Freshly isolated IELs from BALB/c
(a) and DO11.10 (b) mice were gated for CD3+/CD4+,C D 3 +/CD8α+, and CD3+/CD8β+ cells and analyzed for expression of CD25 by ﬂow
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population. (c) Data represent mean ± SEM (N = 5), in three independent experiments. An increased frequency of CD25+ cells can be
observed only in CD8β subset of IELs from DO11.10 mice treated with OVA by oral route.
the induction of apoptosis in lymphocytes present in the
mucosa [23]. The initial hypothesis of our study was that
resistance to the induction of oral tolerance in DO11.10
might be due to failure in the deletion of OVA-speciﬁc
lymphocytes in the intestinal mucosa after ingestion of the
antigen.Indeed,treatmentwithOVAbyoraland/oriproutes
resulted in reduction of IELs in the DO11.10 mice. Besides
that, a remarkable reduction in OVA-speciﬁc cells (KJ1-26)
was observed in small intestine of DO11.10 mice treated
with OVA. Previous work has shown that the administration
of OVA results in marked reduction of mature lymphocytes
KJ1-26+ in the blood and peripheral lymphoid organs [16].
However, a substantial portion of the IELs and lymphocytes
from LP from the DO11.10 mice carries a second nonclono-
typical TCR, probably due to the incomplete allelic exclusion
of the endogenous TCRα during the rearrangement process
in the thymus [21, 24]. Part of the alternative TCR seems
to be speciﬁc to antigens from the intestinal environment as
DO11.10/SCID or DO11.10/RAG2−/− mice do not exhibit
reactivity to antigens from the intestinal microbiota [25, 26].Clinical and Developmental Immunology 11
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Data represent mean ± SEM (N = 5), in three independent experiments. Treatments of BALB/c mice with OVA resulted in increase of the
frequency of Foxp3+ cells in all IEL populations. The oral + ip treatment of DO11.10 mice has increased the frequency of Foxp3+cells in IELs
CD25+.
Thus, a possible explanation for the escape of DO11.10 from
oral tolerance in spite of the occurrence of TCR OVA-speciﬁc
cells deletion would be the activation of T cells bearing
alternative TCR, that would result in local inﬂammatory
response, with activation of nontransgenic IELs carrying
TCR to other than OVA epitopes.
The IELs have phenotype similar to either eﬀector or
eﬀector memory of cells that are present in other peripheral
lymphoid organs [27], presenting a high expression of the
CD103 marker (αEB7), an α-integrin responsible for the
retention of IELs in the intestinal epithelium [28]. This
molecule has been associated to the immuneregulation in
the mucosa as it is expressed by regulatory T lymphocytes
[29,30]aswellasbydendriticcellsinvolvedinthegeneration
of regulatory T cells [31, 32]. IELs from small intestine of
the BALB/c mice treated with OVA orally and/or parenteral
have shown marked increase in the expression of CD103,
in all populations studied: TCD4, TCD8α,a n dT C D 8 β.
Furthermore, IELs from orally treated DO11.10 mice have
shown no changes in the expression of CD103 in any cell
subset. In contrast, TGN immunized intraperitoneally with
OVA showed an accentuated reduction in the expression of
CD103 in these cells.
Several populations of regulatory cells have been de-
scribed in oral tolerance, including IL-10 producer cells
termed Tr1, TGF-β producing cells called Th3 and
TCD4+/CD25+, and its relative importance in the establish-
ment of oral tolerance is still under investigation [1, 20].
SomeofthesestudieshaveemphasizedtheroleoftheCD8αα
IELs in the immunoregulation that occurs in the intestinal
mucosa [33, 34]. In this work, we did not observe changes
in the frequency of this subset of IELs in either BALB/c
or DO11.10 mice immunized orally or parenterally with
OVA.
There is a consensus in the literature that the oral toler-
ance is related to the induction of antigen-speciﬁc regulatory
T cells either by direct or cross-presentation of antigens from
the enterocytes [20, 21, 34]. Our results have shown that
the ingestion of OVA led to an increase in the frequency
of TCD4+/Foxp3+,T C D 8 α+/Foxp3+,T C D 8 β+/Foxp3+,a n d
TCD25+/Foxp3+ amongst the IELs of BALB/c mice, thus
indicating that the establishment of tolerance in wild-type
mouse are associated with the increase of regulatory T cells.
The frequency of TCD25+/Foxp3+ cells has also increased in
the IELs from TGN treated with OVA by oral + ip routes.
However, this increase has not been suﬃcient to inhibit theClinical and Developmental Immunology 13
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inﬂammation that has settled in the small intestinal mucosa
of the TGN after treatment with the protein.
TCD8+ cells also play an important role in the home-
ostatic maintenance of the intestinal epithelium. In this
regard, TCD8αβ suppressor cells have been correlated with
the establishment of antigen speciﬁc oral tolerance [30, 35,
36]. Although the ingestion of OVA leads to an increase in
the frequency of Foxp3+ cells in all populations of IEL from
both BALB/c and DO11.10 mice, our results showed that it
is in the TCD8β+ population of IELs that occurs the highest
frequency of cells carrying this suppression marker.
Due to the exposure of mucosal epithelium to a
huge amount of strange antigens, the cytokines IFN-γ
and interleukin-(IL-)4 are produced spontaneously under
physiological conditions by IELs [37]. In our study, we
observed that the expression of IL-2, IL-10, IFN-γ,T G F - β,
and TNF-α mRNA was smaller in IELS from BALB/c mice
fed OVA and then challenged by ip route than in those that
received OVA only by ip route; the levels of IL-17 and IL-6
mRNA were also reduced, but not signiﬁcantly, in IELs from
BALB/c mice. Instead, IELS from transgenic mice of the oral
+i pg r o u ps h o w e dl e v e l so fI L - 6 ,I F N - γ,T G F - β,a n dT N F - α
mRNAsimilartoorhigherthantheanimalsimmunizedonly
by ip route.
The cytokines IL-10 and TGF-β were always related to
anti-inﬂammatory reactions [1, 20]. More recently, however,
these cytokines have been associated with inﬂammatory
r e a c t i o n sb ya c t i v a t i n gt h ep r o c e s so fd i ﬀerentiation of Th17
cells [38, 39]. TCD4+ cells that secrete IL-17, Th17 cells, are
pathogenic in autoimmune diseases, and their development
and expansion is driven by the cytokines IL-6, TGF-beta, IL-
21, IL-1, and IL-23 [39, 40]. Recent studies have revealed a
considerable number of IL-17-producing cells amongst the
TCD4+ cells in the intestinal mucosa [41]. Although these
cellsareimportanttoestablishaprotectiveimmuneresponse
against intestinal bacteria, they can also be responsible for
inducing inﬂammatory response and the development of
immunological disorders in the presence of IL-6 and/or IL-
23 at mucosal sites [41, 42]. Despite the natural occurrence
of higher expression of IL-6, TGF-β,a n dT N F - α mRNA in
the DO11.10 IELS than in those of BALB/c mice, there was
no signiﬁcant change in IL-17 mRNA after administration of
OVA orally and/or ip in both BALB/c and DO11.10 mice.
Th1-mediated immune responses are considered to be
the primary mediators of most autoimmune and chronic
inﬂammatory diseases. Th17, however, has emerged as a key
protagonist in a number of inﬂammatory diseases. It has
been shown that CD8+ Treg cells can suppress both Th1 and
Th17 responses, being capable of mediating oral tolerance to
OVA independently of their CD4+ counterparts in a normal
immune system [43]. In the present work, the increase in the
frequency of CD8αβ+Foxp3+ cells among IELS of BALB/c
mice after ingestion of OVA could explain the absence or
reduced expression of IL-6, TGF-β,T N F - α,a n dI F N - γ.
Recent studies have shown that inﬂammatory bowel dis-
eases(IBD)suchasulcerativecolitis and Crohn’s disease may
be related to the loss of tolerance to self-antigens or normal
ﬂora [44]. Our results indicate that the structural disorder
observed in epithelium of intestinal villi of transgenic mice
would be a consequence of the preferential expression of
pro-inﬂammatory cytokines by their IELs, in the absence of
an eﬃcient immunoregulation. This inﬂammatory state in
intestinal environment may contribute to the impairment of
oral tolerance to OVA in DO11.10 mice.
5. Conclusion
Takentogether,theresultsofthisstudyindicatethatexposure
to OVA orally causes IELs of the small intestine of TGN mice
assume inﬂammatory characteristics, whereas in BALB/c
antigen intake leads to the development of IELs with char-
acteristics of regulatory cells. Thus, we speculate that the
establishment of oral tolerance in transgenic mice is severely
impaired by changes in the amounts and arrangements of
T cells during the development of intestinal tissues that
compromise the cellularinteractions involved in the process-
es of mucosal immunity.
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